Alberto L Gallotti, Marco Rossi, Marco Conti Nibali, Tommaso Sciortino, Lorenzo G Gay, Guglielmo Puglisi, Antonella Leonetti, Francesco Bruno, Roberta Rudà, Riccardo Soffietti, Gabriella Cerri, Lorenzo Bello
{"title":"Neuro-Oncological Superiority of Supratotal Resection in Lower-Grade Gliomas.","authors":"Alberto L Gallotti, Marco Rossi, Marco Conti Nibali, Tommaso Sciortino, Lorenzo G Gay, Guglielmo Puglisi, Antonella Leonetti, Francesco Bruno, Roberta Rudà, Riccardo Soffietti, Gabriella Cerri, Lorenzo Bello","doi":"10.1093/neuonc/noae264","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Supratotal-Resection (SpTR) is a promising surgical strategy in Lower-grade gliomas (LGGs). SpTR assessment, feasibility and distinctive features, as well as clinical benefit at first and second surgery and on overall-survival must be better characterized. The critical percentage of resection exceeding FLAIR margins to obtain clinical benefit and its impact on long-term functional performance are also undefined.</p><p><strong>Methods: </strong>Included were 704 patients with primary and 439 with recurrent LGGs seen between 2010-2019, who underwent resection with Brain-Mapping-Technique (BMT) aimed at achieving a SpTR without any \"a-priori\" selection. Extent-Of-Resection, evaluated on 3D-FLAIR-MR and categorized according to residual tumor and cavity volume, was associated with Progression-Free-Survival (PFS) and Malignant(M)PFS at first and second surgery, and Overall-Survival by univariate, multivariate and propensity-score analysis. Functional performance was assessed by neuropsychological-NPS evaluation.</p><p><strong>Results: </strong>SpTR evaluation requires volumetric assessment enhanced by brain deformation measurement in parietal tumors; SpTR rate accounts on average for 50.2% and 35.7% at first and second surgery, is higher in grade-2, frontal and temporal locations (at expenses of Total-Resection-TR). Compared to TR, SpTR reduces and postpones first and second recurrences in all molecular subtypes and grades, delays MPFS without difference in rate and prolongs Overall-Survival. A degree of SpTR>120% associates with the lowest recurrence risk. SpTR associates with the best NPS longitudinal course.</p><p><strong>Conclusions: </strong>This study supports feasibility of SpTR in LGGs, its benefit at first and second surgery regardless of molecular subtypes, and on Overall-Survival, significantly reducing recurrence when SpTR>120%; SpTR also associates with the best patients' functional outcome.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noae264","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Supratotal-Resection (SpTR) is a promising surgical strategy in Lower-grade gliomas (LGGs). SpTR assessment, feasibility and distinctive features, as well as clinical benefit at first and second surgery and on overall-survival must be better characterized. The critical percentage of resection exceeding FLAIR margins to obtain clinical benefit and its impact on long-term functional performance are also undefined.
Methods: Included were 704 patients with primary and 439 with recurrent LGGs seen between 2010-2019, who underwent resection with Brain-Mapping-Technique (BMT) aimed at achieving a SpTR without any "a-priori" selection. Extent-Of-Resection, evaluated on 3D-FLAIR-MR and categorized according to residual tumor and cavity volume, was associated with Progression-Free-Survival (PFS) and Malignant(M)PFS at first and second surgery, and Overall-Survival by univariate, multivariate and propensity-score analysis. Functional performance was assessed by neuropsychological-NPS evaluation.
Results: SpTR evaluation requires volumetric assessment enhanced by brain deformation measurement in parietal tumors; SpTR rate accounts on average for 50.2% and 35.7% at first and second surgery, is higher in grade-2, frontal and temporal locations (at expenses of Total-Resection-TR). Compared to TR, SpTR reduces and postpones first and second recurrences in all molecular subtypes and grades, delays MPFS without difference in rate and prolongs Overall-Survival. A degree of SpTR>120% associates with the lowest recurrence risk. SpTR associates with the best NPS longitudinal course.
Conclusions: This study supports feasibility of SpTR in LGGs, its benefit at first and second surgery regardless of molecular subtypes, and on Overall-Survival, significantly reducing recurrence when SpTR>120%; SpTR also associates with the best patients' functional outcome.
期刊介绍:
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field.
The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.